Mon.Oct 28, 2024

article thumbnail

Novartis, Apellis drop dueling datasets as they race for approval in rare form of kidney disease

Fierce Pharma

Novartis and Apellis Pharmaceuticals have rolled out detailed data on iptacopan and pegcetacoplan, respectively, as they race for the prize in a type of rare kidney disease. | Novartis and Apellis dropped new data on their respective meds, iptacopan and pegcetacoplan, in the rare kidney disease C3 glomerulopathy. While Apellis' drug seems to have an efficacy edge based on a cross-trial comparison, Novartis may have gotten the jump by filing for approvals ahead of its competitor.

article thumbnail

This Problem Keeps Hospital Execs Up at Night, Tampa General Hospital CEO Says

MedCity News

The healthcare industry’s inability to coordinate care effectively and at scale is the single biggest issue in the sector, said Tampa General Hospital CEO John Couris. The post This Problem Keeps Hospital Execs Up at Night, Tampa General Hospital CEO Says appeared first on MedCity News.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

Astellas doesn't see eye to eye with Europe on geographic atrophy drug Izervay

Fierce Pharma

While Astellas’ Izervay and Apellis’ Syfovre battle for market share in geographic atrophy (GA) in the United States, both companies are struggling to reach patients in the indication in Europe.&nb | While Astellas’ Izervay and Apellis’ Syfovre battle for market share in geographic atrophy (GA) in the United States, both companies are struggling to reach patients in the indication in Europe.

Medicine 262
article thumbnail

On the front lines of the superbug war, new treatments can’t arrive soon enough

PharmaVoice

As antimicrobial resistance rises, researchers are running out of time to fight each new wave of superbugs. And the funding isn’t enough.

142
142
article thumbnail

AI Strategies for Sales Managers: How to Cut Down on Tedious Admin Work

What if you could help your sellers stop wasting 72% of their day on non-selling activities and focus on bringing in revenue? Incorporating AI in your enablement workflows can help you cut down on busy work, get projects done faster, and let your team (and you!) focus on making a bigger impact. We put together this guide to show you how to use AI to cut time and costs for projects, including collateral creation, development of training videos, and automating tedious processes.

article thumbnail

After prior trial flop, EyePoint's Duravyu bounces back with promising data in DME

Fierce Pharma

Earlier this year, EyePoint Pharmaceuticals’ drug-device combo Duravyu missed the mark in a non-proliferative diabetic retinopathy (NPDR) study, raising doubts about the product’s potential in seve | EyePoint released new diabetic macular edema data Monday that a Mizuho Securities analyst described as "very promising." The trial win provides a needed turnaround for the company's lead candidate Duravyu, which failed a study in non-proliferative diabetic retinopathy earlier this yea

Leads 248
article thumbnail

Novartis to Pay $150M for Monte Rosa Glue Drug in the Clinic for Immunology Indications

MedCity News

Novartis is getting global rights to a Monte Rosa Therapeutic molecular glue degrader drug in early clinical testing as a potential treatment for autoimmune disorders. The deal comes months after the pharma giant landed rights to an Arvinas targeted protein degrader for cancer. The post Novartis to Pay $150M for Monte Rosa Glue Drug in the Clinic for Immunology Indications appeared first on MedCity News.

Pharma 109

More Trending

article thumbnail

Harnessing AI in Pathology: A Vital Tool That Requires Careful Ownership

MedCity News

To fully capitalize on its potential, laboratories must ensure they understand how to use AI effectively. Without this understanding, there’s a risk of undermining the technology’s benefits and potentially harming the industry as a whole. The post Harnessing AI in Pathology: A Vital Tool That Requires Careful Ownership appeared first on MedCity News.

108
108
article thumbnail

Where Big Pharma’s campaign cash is flowing in this election

PharmaVoice

Big Pharma CEOs are hedging all bets by supporting both sides of the aisle in the 2024 election.

Pharma 122
article thumbnail

AbbVie Adds Another Alzheimer’s Prospect With $1.4B Aliada Therapeutics Acquisition

MedCity News

Aliada brings AbbVie an early clinical Alzheimer’s disease drug candidate as well as the platform technology that produced it. Aliada licensed its brain delivery technology from Johnson & Johnson. The post AbbVie Adds Another Alzheimer’s Prospect With $1.4B Aliada Therapeutics Acquisition appeared first on MedCity News.

article thumbnail

MSD, Moderna start phase 3 adjuvant lung cancer trial

pharmaphorum

MSD and Moderna start a third phase 3 trial of their V940 cancer vaccine, their second in early-stage lung cancer.

109
109
article thumbnail

From Diagnosis to Delivery: How AI is Revolutionizing the Patient Experience

Speaker: Simran Kaur, Founder & CEO at Tattva Health Inc.

The healthcare landscape is being revolutionized by AI and cutting-edge digital technologies, reshaping how patients receive care and interact with providers. In this webinar led by Simran Kaur, we will explore how AI-driven solutions are enhancing patient communication, improving care quality, and empowering preventive and predictive medicine. You'll also learn how AI is streamlining healthcare processes, helping providers offer more efficient, personalized care and enabling faster, data-driven

article thumbnail

HealthJoy, Cost Plus Drugs Partner To Reduce Drug Costs for Employers

MedCity News

HealthJoy and Mark Cuban Cost Plus Drug Company have teamed up. Through the partnership, HealthJoy can now direct the employees of its clients to the drug company when it offers a cheaper option for generic drugs. The post HealthJoy, Cost Plus Drugs Partner To Reduce Drug Costs for Employers appeared first on MedCity News.

103
103
article thumbnail

Apple wins in Masimo lawsuit, but its a shallow victory

pharmaphorum

Apple wins in patent infringement lawsuit with wearable maker Masimo, but fails to get the injunction on sales that it sought

Sales 98
article thumbnail

Increasing Efficiency and Reimbursements with Clearinghouses

MedCity News

Clearinghouses are just one great example of how the enhanced exchange of healthcare data can increase efficiency for healthcare providers and the greater healthcare community. The post Increasing Efficiency and Reimbursements with Clearinghouses appeared first on MedCity News.

article thumbnail

Astellas pulls geographic atrophy drug filing in the EU

pharmaphorum

Astellas confirmed today it will withdraw its EMA filing for avacincaptad pegol as a treatment for eye disorder geographic atrophy in the EU

90
article thumbnail

How to Prove Marketing Value: Demonstrate Content ROI and Contribution to Sales

Every marketer knows how important it is to prove their efforts drive sales opportunities, but that’s easier said than done. When problems like sales and marketing misalignment, lack of data, and wasted efforts persist, marketers can’t measure, prove, or increase their impact on revenue at a time when demonstrating marketing value is critical. Using analyst and expert data, this guide to marketing impact and content attribution explains: How B2B buyers use content The most common types of conten

article thumbnail

FDA approves Iterum’s ORLYNVAH NDA for uUTI treatment

Pharmaceutical Technology

The US FDA has approved Iterum Therapeutics' NDA for ORLYNVAH to treat uncomplicated urinary tract infections (uUTIs).

FDA 98
article thumbnail

Novartis eyes year-end filing in US for Fabhalta in C3G

pharmaphorum

Novartis says Fabhalta shows sustained efficacy in rare disease C3G over 12 months, as it prepares for an FDA filing later this year

FDA 88
article thumbnail

EU Critical Medicines Act: closer to ending overreliance on Asian manufacturers

Pharmaceutical Technology

China's virtual monopoly on the supply of many APIs could be dangerous for the security of medicine supply to Western countries.

article thumbnail

ACG 2024: J&J data reveals new Crohn’s treatment option

European Pharmaceutical Review

Phase III findings showed that TREMFYA ® (guselkumab) is the first IL-23 inhibitor to demonstrate results in subcutaneous induction and maintenance therapy of Crohn’s disease. New Phase III data from Johnson & Johnson has shown that the biologic could become the first IL-23 treatment to offer both a subcutaneous and intravenous induction regimen for the autoimmune condition.

article thumbnail

Optimizing Clinical Supply Strategy: Navigating Challenges & Finding Your Ideal Model

article thumbnail

Transforming pharmaceutical R&D: the impact of digital technologies on drug discovery and development

Pharmaceutical Technology

The Pharmaceutical Automation and Digitalisation Congress (AUTOMA+) 2024 is a strategic platform for discussion and collaboration among decision makers, researchers and technologists who understand and follow this tendency.

article thumbnail

There’s no Light at the End of the AI Tunnel, Unless You Planned for It

ALULA

Wasn’t AI supposed to make our working lives easier? A recent survey by Upwork Inc., one of the world’s biggest online freelance worker marketplaces, found that while 96% of C-Suite leaders said they expected AI to boost productivity, 77% of employees reported that AI had “added to their workload” and half said “they have no idea how to achieve the productivity gains their employers expect.

52
article thumbnail

Redlining’s lasting impact on asthma disparities

Pharmaceutical Technology

The enduring effects of redlining on public health, particularly on asthma prevalence, provide a striking example of how discriminatory housing policies from the 20th century continue to shape the well-being of marginalised communities affected by this practice today.

59
article thumbnail

Merck, Moderna Launch Phase III Trial of V940 in Combination with Keytruda for Resectable Non-Small Cell Lung Cancer

PharmExec

Collaboration seeks to advance the treatment of non-small cell lung cancer by combining Keytruda with Moderna’s novel neoantigen therapy, which has shown positive results across cancer types.

52
article thumbnail

Increase Revenue With Better, Faster Sales Onboarding

Quotas need to be hit. Revenue goals need to be met. This reality makes shortening sales onboarding time a top priority. Organizations with a standard onboarding process boost employee retention by 58% and increase productivity by 50%. Unfortunately, many companies struggle with inefficient processes that lead to high turnover and missed revenue opportunities.

article thumbnail

Tech Transfer in the New World of New Modalities

PharmaTech

Emerging therapies, patient-centric medicines, and the ever-changing world of bio/pharmaceuticals complicate technology transfer.

article thumbnail

Strengthening Regulatory Framework for Compounded Medications

PharmExec

Scott Brunner, CEO, and Tenille Davis, Chief Advocacy Officer, of the Alliance for Pharmacy Compounding explain how the regulatory framework for compounded medications can be further strengthened to ensure quality and safety, while still maintaining flexibility to address patient needs.

Medical 52
article thumbnail

Access Insights 2024: Reassessing Pricing and Commercialization Approaches

Pharmaceutical Commerce

Albert Thigpen, co-founder, Talentwise Consulting, explains how to use these tactics in order to anticipate the future US healthcare policy environment.

article thumbnail

Survey: 8 in 10 Patients Believe Immunization Protects Them From Public Health Threats

Pharmacy Times

Champions for Vaccine Education, Equity, and Progress reported that the majority of pharmacists believe that it is important to prioritize vaccine development and distribution.

article thumbnail

European Clinical Supply Planning: Balancing Cost, Flexibility and Time

article thumbnail

Rentschler Biopharma to Construct New Buffer Media Facility in Germany

Pharmaceutical Commerce

With the design of the new 360,000 square-foot building, the CDMO’s goal is to continue to modernize its Laupheim site.

Media 59
article thumbnail

AbbVie Agrees to Terms to Acquire Aliada Therapeutics

PharmExec

OncLive serves as the connection to oncology, including groundbreaking cancer news and interviews with top oncologists in multimedia formats.

52
article thumbnail

UAE’s clinical trials space matures with experience from Covid-19

Pharmaceutical Technology

At the Outsourcing in Clinical Trials conference, Rohan Simon from the UAE CRO IROS, spoke about the region’s clinical trials landscape.

52
article thumbnail

Pharma Pulse 10/28/24: Operating Without a Commercial Blueprint, The Dilemma of Childhood Vaccines Post Pandemic & more

PharmExec

OncLive serves as the connection to oncology, including groundbreaking cancer news and interviews with top oncologists in multimedia formats.

Pharma 52
article thumbnail

Using Generative AI in Sales: Pros, Cons, and Considerations According to Sellers

Are your sellers unsure about using AI in their day-to-day workflows? Or are they eager to try but uncertain where to start? They might be asking: Which tasks are best suited for AI? How will using AI affect my relationship with my customers? With so many tools available, which ones are the most useful to me? To help answer these and other common questions about using AI during the sales cycle, we surveyed B2B sellers who were early adopters to get their insight and advice about how to use gen A